Point72 Asset Management L.P. increased its stake in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 13.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 220,600 shares of the biopharmaceutical company’s stock after buying an additional 25,500 shares during the period. Point72 Asset Management L.P. owned about 0.89% of Intercept Pharmaceuticals worth $24,950,000 as of its most recent filing with the SEC.
A number of other large investors also recently bought and sold shares of ICPT. WFG Advisors LP raised its stake in shares of Intercept Pharmaceuticals by 197.1% in the fourth quarter. WFG Advisors LP now owns 2,956 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,961 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the last quarter. US Bancorp DE acquired a new stake in shares of Intercept Pharmaceuticals during the first quarter valued at about $130,000. Quantbot Technologies LP acquired a new stake in shares of Intercept Pharmaceuticals during the first quarter valued at about $170,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Intercept Pharmaceuticals by 39.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,630 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 462 shares during the last quarter. 84.35% of the stock is currently owned by institutional investors and hedge funds.
Shares of Intercept Pharmaceuticals, Inc. (ICPT) traded down 1.50% on Monday, reaching $130.30. 145,919 shares of the company were exchanged. The firm’s market capitalization is $3.26 billion. Intercept Pharmaceuticals, Inc. has a 12-month low of $96.63 and a 12-month high of $177.93. The company’s 50 day moving average is $116.91 and its 200 day moving average is $114.33.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.27) by $0.66. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. The business had revenue of $21 million during the quarter, compared to the consensus estimate of $15.88 million. During the same quarter last year, the company posted ($5.17) earnings per share. The firm’s quarterly revenue was up 4566.7% compared to the same quarter last year. Analysts forecast that Intercept Pharmaceuticals, Inc. will post ($14.50) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Point72 Asset Management L.P. Boosts Position in Intercept Pharmaceuticals, Inc. (ICPT)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://sportsperspectives.com/2017/06/26/point72-asset-management-l-p-boosts-position-in-intercept-pharmaceuticals-inc-icpt.html.
Several equities research analysts have issued reports on the stock. Citigroup Inc. set a $240.00 price target on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, February 28th. Cowen and Company reiterated a “buy” rating and issued a $225.00 price target on shares of Intercept Pharmaceuticals in a research note on Monday, April 24th. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 8th. Credit Suisse Group lifted their price target on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the company an “outperform” rating in a research note on Friday, May 5th. Finally, BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Intercept Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $190.98.
In related news, CMO David Shapiro sold 1,117 shares of the firm’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $112.18, for a total transaction of $125,305.06. Following the completion of the sale, the chief marketing officer now owns 46,582 shares in the company, valued at $5,225,568.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lisa Bright sold 698 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $110.73, for a total transaction of $77,289.54. Following the sale, the insider now owns 24,711 shares of the company’s stock, valued at approximately $2,736,249.03. The disclosure for this sale can be found here. Insiders have sold 4,016 shares of company stock valued at $452,624 in the last 90 days. 4.50% of the stock is currently owned by corporate insiders.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.